Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e
How this was made
The 30-second read
Why it matters
The key incremental information is longer follow-up showing sustained complete responses without additional RRP treatments, alongside confirmation of seven-year orphan drug market exclusivity and absence of new adverse safety events.
Market read
For PGEN, the durability datapoints and exclusivity are directly supportive for the PAPZIMEOS commercial thesis and can drive incremental re-rating if investors were waiting for longer follow-up.
What to watch
Market may discount durability claims if commercial uptake/coverage dynamics are not addressed; also, exclusivity timing and competitive landscape (off-label/surgery alternatives) aren’t quantified here.
Background
PAPZIMEOS (zopapogene imadenovec-drba) is the first FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP), and this release updates pivotal-study durability presented at ASCO.
Ticker impact
Precigen (PGEN) reported new long-term durability follow-up for PAPZIMEOS, including 83% ongoing complete responses and FDA seven-year exclusivity.
Likely supportive for near-term sentiment and valuation multiples; magnitude depends on how much the market already priced in long-term durability.
The release adds specific long-term datapoints (36+ months, 5 responders beyond 4 years, no new safety events) and confirms seven-year market exclusivity, both directly relevant to PAPZIMEOS’s commercial outlook.
Market effects
Reinforces investor appetite for durable-response immunotherapies in rare diseases; may modestly lift sentiment for similar platform-based programs.
Primarily US-focused given FDA exclusivity and ASCO presentation; limited direct regional spillover.
US regulatory exclusivity and clinical durability can influence global partner/expansion expectations, but article is US-centric.
Counterpoint
Durability follow-up is still limited by small responder counts (18 complete responders), and median duration of complete response is not reached.
Key entities
- companyPrecigen, Inc.
Commercial-stage biopharmaceutical company announcing updated long-term durability data and FDA seven-year market exclusivity for PAPZIMEOS.
- drugPAPZIMEOS (zopapogene imadenovec-drba)
Non-replicating adenoviral vector immunotherapy for adult RRP; durability update shows ongoing complete responses beyond 4 years for some responders.
- regulatorUS FDA
Granted seven-year orphan drug market exclusivity to PAPZIMEOS.
